KYAN Therapeutics Technology Platform Identifies Novel and Effective Nucleic Acid Therapies for MYC-Induced Liver Cancer

Study published in Bioengineering & Translational Medicine

SINGAPORE, SINGAPORE, Sept. 17, 2022 / — MYC is a transcription factor that is deregulated in over 70% of human cancers, making it an important target that has unfortunately been considered “untreatable” for many years. Although synthetic lethality has offered a promising parallel approach targeting MYC-dependent vulnerabilities in cancer, there is as yet no synthetic lethality therapy directed against MYC-driven cancers that has been approved for clinical use. A major challenge in achieving MYC synthetic lethality targets in clinical settings is the need to prioritize targets by therapeutic potential for each MYC-driven cancer type due to differences in tumors within each type.

Considering the need for target prioritization and an increase in exploration of combination therapies against MYC-driven cancers, investigators in this study used KYAN’s hybrid experimental-analytical platform to find lethal synthetic MYC targets with the greatest therapeutic potential and compared their therapeutic properties. value to current standard of care drugs in hepatocellular carcinoma (HCC) driven by MYC. The researchers further used technology from KYAN and the Agency for Science, Technology and Research (A*STAR) Institute of Molecular and Cellular Biology (IMCB) to identify a two-drug combination of novel splicing-switching oligonucleotides (SSO) as Promising therapeutic candidates for MYC-driven HCC.

“We are delighted that our collaboration with IMCB is already generating such exciting results,” said Hugo Saavedra, CEO of KYAN Therapeutics. “Being able to help drug discovery is another valuable tool that helps us create solutions for better cancer care.”

About KYAN

KYAN Therapeutics is a biotechnology company with a mission to close the gap in cancer care by advancing revolutionary technologies. Our technology platforms were developed in collaboration with UCLA and the National University of Singapore, combining biological experiments and small data AI to define how therapies are developed and delivered to patients. From drug development to personalized medicine, KYAN offers an efficient solution to identify the optimal outcome from millions of possible drug dose combinations. KYAN’s technology has been peer-reviewed in several reputable, high-impact factor journals and has been implemented in multiple clinical studies.

See also  Despite interoperability challenges, technology can help advance hybrid care

For more details visit

Media contact
Lisa Chow
email us here
Visit us on social networks:

Leave a Comment